COVID-19 “Cease Fire” for the United States on April 23, 2020 and successful ‘Opening Up America Again’ initiative predicted
Atossa Therapeutics, Inc. (ATOS)
Last atossa therapeutics, inc. earnings: 11/13 04:10 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.atossagenetics.com
Company Research
Source: GlobeNewswire
SEATTLE, April 17, 2020 (GLOBE NEWSWIRE) -- Physician-scientist and inventor Dr. Steven Quay, MD, PhD announced today that his proprietary model of COVID-19 case growth predicts that the United States as a whole will be able to declare a SARS-CoV-2 “cease fire” on April 23, 2020, although individual states will continue to battle the pandemic. His model has successfully predicted a similar success in nine European countries, some of which are beginning to successfully reopen their economies. He also believes the ‘Opening Up America Again’ initiative will be successful based on his firsthand witnessing of Taiwan’s policies and practices. Many of the Administration’s initiatives have been successfully used by Taiwan to contain the virus and then permit the country to return to near normal. Taiwan is considered to have the most successful SARS-CoV-2 response in the world, with a total of 395 cases and 6 deaths. The case rate in Taiwan is 17 per million population compared to Spain
Show less
Read more
Impact Snapshot
Event Time:
ATOS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATOS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATOS alerts
High impacting Atossa Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ATOS
News
- Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research [Yahoo! Finance]Yahoo! Finance
- Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer ResearchGlobeNewswire
- Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer SymposiumGlobeNewswire
- Atossa Therapeutics, Inc. (NASDAQ: ATOS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its price target raised by analysts at HC Wainwright from $6.00 to $7.00. They now have a "buy" rating on the stock.MarketBeat
ATOS
Earnings
- 11/12/24 - Miss
ATOS
Sec Filings
- 11/19/24 - Form 8-K
- 11/19/24 - Form 424B5
- 11/12/24 - Form SC
- ATOS's page on the SEC website